A single immunotherapy infusion typically takes 30 to 90 minutes, but the full course of treatment usually spans one to two years depending on the type of cancer and how well it’s working. Those two numbers, the per-session time and the overall duration, are what most people want to know when they’re facing immunotherapy for the first time. The reality is that “how long” has several layers, from the time you spend in the chair each visit to when your first scan shows results.
How Long Each Infusion Session Takes
The infusion itself, once the drug is prepared and flowing, lasts 30 to 90 minutes for most checkpoint inhibitors. That range accounts for any pre-medications you might receive beforehand, like antihistamines or anti-nausea drugs. Plan on being at the infusion center longer than that, though. Check-in, vitals, IV setup, and a post-infusion monitoring period (typically 30 to 60 minutes to watch for reactions) can stretch a single visit to two or three hours total.
Some treatment plans combine immunotherapy with chemotherapy or other drugs. These multi-drug regimens can take significantly longer, up to eight hours in some cases, particularly when drugs like cisplatin or rituximab are part of the protocol. Your oncology team will tell you in advance what to expect for your specific combination so you can plan your day.
How Often You’ll Go for Treatment
Most checkpoint inhibitor schedules fall into cycles of every two, three, four, or six weeks. The exact interval depends on which drug you’re receiving and what your oncologist determines is best for your situation. Early in treatment, visits tend to be more frequent. As you continue and your team confirms you’re tolerating the therapy well, some schedules allow for longer gaps between infusions. A six-week cycle obviously means far fewer clinic days per year than a two-week cycle, which can make a real difference in quality of life over a long treatment course.
Total Treatment Duration
There’s no universal rule for how long the full course of immunotherapy lasts, and oncologists worldwide are still working to define the optimal stopping point. That said, clear patterns have emerged from clinical trials and treatment guidelines.
For advanced cancers, most clinical studies use a two-year treatment duration as the standard. This applies broadly across advanced lung cancer, kidney cancer, liver cancer, melanoma, and several others. Two years is also the typical benchmark for combination approaches that pair immunotherapy with drugs that block tumor blood supply, and for dual-immunotherapy regimens used in cancers like advanced kidney cancer, lung cancer, and melanoma.
For locally advanced cancers that haven’t spread widely, consolidation immunotherapy (given after radiation or chemotherapy to keep the cancer in check) usually runs one to two years. And for early to mid-stage cancers treated with surgery, adjuvant immunotherapy given afterward to reduce the risk of recurrence is typically recommended for one year.
Some patients stop earlier. In advanced melanoma, for example, someone who achieves a complete response on scans and has been on treatment for at least six months may be a candidate for stopping. If the cancer has partially shrunk or stabilized after two years, stopping can also be considered. These decisions are highly individual and depend on how the cancer is responding, what side effects you’re experiencing, and your overall health.
When You’ll Know If It’s Working
Your first scan to assess response will typically happen 6 to 12 weeks after starting treatment. Oncologists look for early tumor shrinkage, often defined as a 10 to 20 percent reduction in the size of target tumors. In lung cancer, kidney cancer, colorectal cancer, and pancreatic cancer, studies consistently show that patients whose tumors shrink by at least 20 percent within the first six to eight weeks tend to have better long-term outcomes.
One important thing to know: immunotherapy can cause something called pseudoprogression, where tumors appear to grow on early scans before they actually start shrinking. This happens because immune cells flood into the tumor, temporarily making it look larger on imaging. This phenomenon typically resolves by week 12 and is rare after that point. If your first scan looks concerning, your oncologist may recommend waiting and rescanning before changing your treatment plan.
When Side Effects Typically Appear
Immunotherapy side effects follow a fairly predictable timeline. Because these drugs work by activating your immune system, the side effects are essentially your immune system overreacting against healthy tissues. Skin reactions like rashes tend to show up first, often within two to five weeks of starting treatment. Digestive issues such as diarrhea or colitis typically appear around five to seven weeks. Kidney-related effects are the slowest to develop, with a median onset around 15 weeks.
Mild side effects tend to appear earlier than severe ones. For certain immunotherapy drugs, the median time to onset for all side effects is about 8 weeks, while serious side effects don’t surface until a median of roughly 28 weeks. Combination immunotherapy regimens tend to cause side effects a bit sooner, around 6 weeks on average, with serious effects appearing closer to 8 weeks. This is useful to know because it means your medical team will be monitoring you closely at specific intervals based on which side effects are most likely at each stage.
CAR-T Therapy Has a Different Timeline
If your immunotherapy involves CAR-T cell therapy, a treatment where your own immune cells are collected, genetically modified to attack cancer, and infused back into your body, the timeline looks quite different from standard infusions. The manufacturing process alone takes 21 to 35 days from the time your cells are collected to when they’re ready for infusion. During that waiting period, you may receive a short course of chemotherapy to prepare your body.
The actual CAR-T infusion is a single event, not a recurring schedule. Recovery, however, requires close monitoring for at least several weeks afterward, and some patients are hospitalized during the initial period to manage potential reactions. Newer manufacturing techniques are pushing production times down dramatically, with some experimental approaches generating modified cells in as few as three days, but the standard timeline remains three to five weeks for most patients today.
Your Immune System Keeps Working After Treatment Ends
One of the most distinctive features of immunotherapy is that its effects don’t necessarily stop when the infusions do. Unlike chemotherapy, which only works while the drug is in your body, immunotherapy teaches your immune system to recognize and attack cancer cells. That immune “memory” can persist long after your last dose, continuing to provide protection against the cancer returning. This is one reason oncologists are comfortable stopping treatment at the one- or two-year mark in patients who are responding well, rather than continuing indefinitely. The immune system, once trained, may keep doing its job on its own.